< Back to previous page


A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology.

Journal Contribution - Journal Article

Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient's blood milieu with immuno-oncological applications are rare. We recently established a "first-in-class" serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to "mimic" in situ patient's serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification.
Issue: 1
Volume: 11
Number of pages: 3
Publication year:2022